NCT06239220 2026-02-27PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCCDana-Farber Cancer InstitutePhase 2 Recruiting25 enrolled
NCT03127098 2024-08-06QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing CancerNantCell, Inc.Phase 1/2 Terminated3 enrolled 6 charts
NCT01727076 2017-09-15Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck CancerNational Cancer Institute (NCI)Phase 1 Completed20 enrolled